Last reviewed · How we verify
DWC202313, DWC202314P
DWC202313 and DWC202314P are botulinum toxin type A inhibitors.
DWC202313 and DWC202314P are botulinum toxin type A inhibitors. Used for Chronic sialorrhea, Upper limb spasticity.
At a glance
| Generic name | DWC202313, DWC202314P |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | botulinum toxin type A inhibitor |
| Target | botulinum toxin type A |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
They work by blocking the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation and potentially reducing symptoms of certain conditions.
Approved indications
- Chronic sialorrhea
- Upper limb spasticity
Common side effects
- Injection site pain
- Muscle weakness
- Dysphagia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |